RIOK2 Antibody (YA8047)

RIOK2 (RIO kinase 2) is an evolutionarily conserved atypical serine/threonine kinase that functions primarily as a ribosome biogenesis factor required for the export, assembly, and cytoplasmic maturation of pre-40S ribosomal subunits, thereby supporting efficient mRNA translation and protein synthesis^[1][2]. Mechanistically, RIOK2 associates with late pre-40S particles and participates in the final steps of small ribosomal subunit maturation, where its regulated release and nuclear recycling are required for productive ribosome assembly^[2][3]. The Ras/MAPK pathway directly connects extracellular growth signals to ribosome biogenesis through RSK-mediated phosphorylation of RIOK2, which promotes pre-40S particle maturation, optimal protein synthesis, and cell proliferation^[2]. Consistent with its central role in translational control, RIOK2 is essential for hematopoietic stem and progenitor cell differentiation and for maintenance of mature blood cells in vivo, highlighting the physiological importance of RIOK2-dependent ribosome production^[1]. Disease studies further implicate RIOK2 in multiple malignancies, including glioblastoma, acute myeloid leukemia, liver cancer, prostate cancer, and non-small cell lung cancer, where elevated expression is associated with tumor progression and proliferative phenotypes^[4][5]. Compared with related isoforms, RIOK1, RIOK2, and RIOK3 belong to the same atypical kinase family; however, RIOK2 is most strongly linked to pre-40S maturation, whereas RIOK3 is not required for canonical 40S biogenesis and RIOK1 displays distinct context-dependent functions in cell growth regulation^[1][5]. Therefore, modulation of RIOK2 activity and phosphorylation status provides a valuable experimental framework for investigating ribosome biogenesis, translational regulation, hematopoiesis, and cancer biology^[2][1][4].